Regulation

Newsletter, Regulation

Who’s Calling for a Hearing on Rescheduling?

An excerpt from the Cannabis Wire Daily newsletter.

Regulation

Pres. Biden Formally Announces DOJ Will Move to Reclassify Cannabis

Now, the public will have a chance to weigh in on cannabis rescheduling.

Regulation

In Historic Move, DEA Will Recommend Cannabis Reclassification

The rescheduling of cannabis, once complete, will mark an historic shift in U.S. cannabis policy, and is likely to send ripple effects across the globe.

Regulation

OSHA Officials Lay Out Cannabis Workplace Safety Landscape 

Even though cannabis remains federally illegal, that hasn’t stopped OSHA officials from collecting data on potential workplace safety hazards in the nascent industry.

Regulation

House Lawmakers Push Top FDA Official on Hemp Products and Cannabis Rescheduling 

The conversation covered the proliferation of intoxicating hemp products, as well as the timeline for the federal review of whether to move cannabis from Schedule I to III.

Regulation

FDA Officials Discuss Future of Cannabis Regulation at Food & Drug Law Institute 

The conversation ranged from Congressional inaction on CBD to the myriad unregulated cannabinoid products on shelves today.

Regulation

Cannabis Regulators Work to Forge a Path on Interstate Commerce 

States along the west coast have already passed laws to allow for “controlled” interstate commerce – when federal law changes.

Regulation

What Else Is In HHS’ Cannabis Rescheduling Docs?

Many groups’ work, from CANNRA to the National Academies of Sciences, Engineering, and Medicine, informed a federal recommendation to reclassify cannabis.

Regulation

State Medical Cannabis Programs, Booming Research, Informed HHS Recommendation to Reclassify Cannabis

Newly released documents from the Dept. of Health and Human Services detail the agency’s recommendation to the DEA to put cannabis in Schedule III.

Regulation

National Academies’ Cannabis Committee Convenes Again

The second meeting of the Committee on the Public Health Consequences of Changes in the Cannabis Policy Landscape is underway this week. Here’s what happened on day one.

Regulation

How Many Cannabis Products Have Been Recalled in 2023? You Might Never Know. 

There’s no consistency among states about how to disclose recalled cannabis products.

Regulation

New CDC Report Explores Asthma Risks for Cannabis Workers

The CDC, NIOSH, and the Massachusetts Department of Public Health published reports and bulletins this week following their investigations into a cannabis worker’s death in 2022.

Regulation

FDA Looks Back On Fifty Years of Cannabis Research, Prepares for Growth Ahead

FDA researchers published an article this week titled “From Our Perspective: FDA’s 50 Years of Experience with Cannabis Research Helping to Support Tomorrow’s Cannabis Drug Development.”

Policy, Regulation

American Enterprise Institute Hosts Cannabis Conversation: “You Can Either Get on the Bus or You Can Get Hit By It.” 

The center-right think tank hosted a cannabis policy discussion in D.C. on Wednesday focused on the future of federal reforms.

Regulation

U.S. Census Bureau Releases First Cannabis Data Product 

The “experimental data product” focused on excise sales tax revenue is the Bureau’s most comprehensive cannabis data collection effort to date.

Regulation

Federal Cannabis Review Reaches Milestone as HHS Recommends Schedule III Reclassification

The scheduling review, prompted by Pres. Biden in October, could reshape the cannabis policy landscape in the U.S. Now, the DEA will decide.